8-K: Evofem Biosciences Faces Delisting Notice from OTCQB Due to Low Stock Price

Evofem Biosciences received a notice from OTC Markets Group on January 6, 2025, indicating non-compliance with the minimum bid price requirement for continued listing on the OTCQB Venture Market.

Summary

• Evofem Biosciences received a delisting notice from the OTC Markets Group (OTCQB) on January 6, 2025.
• The notice states that Evofem's common stock price has fallen below $0.01 per share for 30 consecutive calendar days, violating the OTCQB's minimum bid price requirement.
• Evofem has a 90-day compliance period, until April 6, 2025, to regain compliance.
• Compliance can be achieved if the stock price is equal to or greater than $0.01 for ten consecutive trading days during the compliance period.
• If compliance is not achieved by April 6, 2025, Evofem's common stock will be removed from the OTCQB.
• Evofem intends to monitor the stock price and consider options to regain compliance.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the delisting notice and the uncertainty surrounding the company's ability to regain compliance. The company's future is uncertain.

Positives

• The OTC Notice has no immediate effect on the listing of the Company’s common stock on OTCQB, and, therefore, the Company’s listing remains fully effective.
• The company has a 90-day grace period to regain compliance.

Negatives

• Evofem's common stock price has fallen below the minimum bid price requirement of $0.01 per share for 30 consecutive calendar days.
• Failure to regain compliance by April 6, 2025, will result in delisting from the OTCQB Venture Market.

Risks

• There is no guarantee that Evofem will be able to regain compliance with the minimum bid price requirement during the compliance period.
• Delisting from the OTCQB could negatively impact the company's stock price and investor confidence.

Future Outlook

The company intends to actively monitor the closing bid price for the Company’s common stock between now and April 6, 2025, and will consider available options to resolve the deficiency and regain compliance with the Minimum Bid Price Requirement.

Management Comments

• Saundra Pelletier, Chief Executive Officer, signed the report on behalf of Evofem Biosciences.

Industry Context

Many small cap biotech companies face challenges in maintaining stock prices above minimum listing requirements, especially those reliant on a single product or facing market headwinds.

Comparison to Industry Standards

• Companies like Evofem, which are in the development or commercialization stage of their lead products, often face stock price volatility.
• Compared to other companies listed on OTCQB, Evofem's situation is not unique, as many micro-cap companies struggle to maintain listing requirements.
• Similar situations have occurred with companies like Aeterna Zentaris and Diffusion Pharmaceuticals, which have also faced delisting warnings due to low stock prices.

Stakeholder Impact

• Shareholders may experience a decline in the value of their investment if the company is delisted.
• Employees may face uncertainty regarding their job security if the company's financial situation worsens.

Next Steps

• Evofem will actively monitor its stock price.
• Evofem will consider options to resolve the deficiency and regain compliance with the OTCQB listing standards.

Key Dates